ISPE Announces Acting CEO and President
Tim Howard will assume the role of acting ISPE CEO and president after John Bournas steps down from the positions.
On Jan. 8, 2020, the International Society for Pharmaceutical Engineering (ISPE) announced that Tim Howard, vice president of Strategic Development for CAI, will assume the role of acting ISPE CEO and president after John Bournas steps down from those positions. Howard will lead the company as the ISPE board searches for a permanent replacement.
Howard previously worked with Eli Lilly, is a former naval nuclear submarine officer, and was licensed as a senior reactor operator on a commercial nuclear power plant before serving in various senior roles at CAI. Howard also served on the International Board of Directors of ISPE from 2011 to 2019, serving as chair in 2018.
Source: ISPE
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
